ClinicalTrials.gg
CompletedNCT00271284VARIABILITEUpdated Dec 7, 2009

Efficacy Study on the Control of Blood Glucose Concentration in Type 1 Diabetic Patients

A Phase 3 interventional study of insulin glulisine / insulin glargine and insulin glulisin / insulin detemir in Diabetes Mellitus, Type 1, sponsored by Sanofi. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-12-07.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing insulin glulisine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. insulin glulisine · Diabetes Mellitus, Type 1.

Enrollment
11th of 25
88 · median 72
Started
2005
with 4 others
Phase 3
6 of 26
none open now
Registered
3rd of 26
by date
Lead sponsor
15 of 26
Sanofi

Among the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 1, this one is the 11th largest by enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2005, is one of 6 in phase 3, and was the 3rd registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About insulin glulisine

insulin glulisine: first FDA approval 2004 (APIDRA SOLOSTAR), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 1 as a file.
02

Study summary

·Main objective: To compare the variability of fasting capillary blood glucose concentration, observed with insulin glargine combined with insulin glulisine and with insulin detemir combined with insulin glulisine, in type 1 diabetics. It is a non-inferiority study.

·Secondary objectives:

Efficacy:

  • To compare the variability of blood glucose concentration before the evening meal, observed with insulin glargine combined with insulin glulisine and with insulin detemir combined with insulin glulisine, in type 1 diabetics.
  • To record the intra- and inter-daily variability using the MAGE and MODD indices [1,2,3,4]
  • To compare the glycaemic profiles (7 points)
  • To evaluate the HbA1c concentration, at the end of each period of treatment, weight change, the dose of insulin used and the number of daily injections.

Tolerance:

  • To record undesirable events
  • To evaluate the safety in use from the record of episodes of hypoglycaemia (symptomatic, diurnal, nocturnal, severe).
03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Belonging to a social security scheme or covered by such a scheme
  • With type 1 diabetes (defined as a concentration of C-peptide \< 0.1 nmol//l and a fasting blood glucose of >= 1.26 g/l), diagnosed not less than 5 years previously
  • Treated for at least 6 months by intensive insulin treatment, following a basal-bolus system, using insulin glargine (Lantus®) as basal insulin. During the study, this insulin will administered in the evening
  • Trained in the titration of prandial insulin (the dose of rapid insulin decided at each mealtime depending on the composition of the meal)
  • With an level of \<= 8.5% at the inclusion visit
  • Capable of checking their blood glucose concentration using the material supplied by the sponsor: blood glucose meter and patient notebook
  • Able to eat 3 regular daily meals on the days for recording the blood glucose cycle and similarly as much as possible on other days throughout the length of the study
  • Able to continue their usual daily activities during the study
  • Women of should be using an effective method of
  • Fundal examination result less than a year old available

Exclusion criteria

Exclusion Criteria:

  • Recent history of severe hypoglycaemia (at least 2 events in the 6 months prior to inclusion)
  • An episode of acidocetosis in the 3 months prior to inclusion
  • Proliferating retinopathy, defined as having required treatment by surgery or photocoagulation, in the 6 months prior to visit 1, or non-stabilised (rapidly developing) retinopathy which may require photocoagulation or surgery
  • Pancreatectomy
  • Altered hepatic function ( or ALT >= 2.5 x normal, in the initial measurements)
  • Altered renal function (plasma creatinine > 1.5 mg/dl)
  • Acute infection
  • Acute or chronic metabolic acidosis
  • Gastroparesis
  • History of cancer in the last 5 years
  • Medically significant cardiovascular, hepatic, neurological or endocrine disease or any other significant disease making carrying out the protocol or interpreting the trial results difficult
  • History of drug or alcohol abuse
  • Subject likely to receive treatment during the trial which is not authorised in the protocol (see Section 6.2), in particular, treatment by whatever the route of administration or dose.
  • Antidiabetic treatment by products other than those supplied within the framework of this study
  • Treatment by another product undergoing development during the 3 months prior to inclusion in the trial
  • to one of the study products (insulin glargine, insulin detemir, insulin glulisine) or to one of the present in the insulin preparations, used in the study
  • Working at night
  • Pregnancy
  • Breast-feeding
  • Mental state making the subject incapable of understanding the objectives and possible consequences of the trial
  • Subject unable to submit to the restrictions of the protocol (e.g. uncooperative, incapable of attending monitoring visits and probably incapable of finishing the trial)
  • Subject deprived of his liberty because of an administrative or legal decision
  • The investigator or any member of the team or close to the investigator directly implicated in the trial particularly assistant doctors, pharmacists, nurses, trial coordinator, etc.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    I

    Drug: insulin glulisine / insulin glargine

  • Active comparator
    II

    Drug: insulin glulisin / insulin detemir

Interventions

  • Druginsulin glulisine / insulin glargine

    Drug pages: Insulin glulisine · Insulin Glargine

    insulin glargine administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00

  • Druginsulin glulisin / insulin detemir

    insulin detemir administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00

06

What researchers measure

Primary outcomes

  1. Efficacy data : fasting blood glucose concentration

    Time frame: read daily during the last 2 months of each period

Secondary outcomes

  1. Tolerance data : undesirable events including episodes of hypoglycaemia

    Time frame: throughout the study

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Paris, France
08

References and documents

Publications

  • Renard E, Dubois-Laforgue D, Guerci B; Variability Study Group. Non-inferiority of insulin glargine versus insulin detemir on blood glucose variability in type 1 diabetes patients: a multicenter, randomized, crossover study. Diabetes Technol Ther. 2011 Dec;13(12):1213-8. doi: 10.1089/dia.2011.0063. Epub 2011 Aug 2. PubMed 21810024 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2005
First posted
Dec 30, 2005
Start
Oct 2005
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Last update
Dec 7, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00271284
Lead sponsor
Sanofi
First posted
Dec 30, 2005
Start date
Oct 2005
Primary completion
Sep 2008
Completion
Sep 2008
Last update
Dec 7, 2009

Study contacts

Marie SEBILLE, Dr
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin glulisine · Insulin Glargine

Start the discussion